NCT03462251: Ribociclib and Aromatase Inhibitor or Paclitaxel and Bevacizumab for Metastatic Breast Cancer in First Line

NCT03462251
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known presence of cerebral metastases unless at least 4 weeks from prior therapy completion- see trial for details
https://ClinicalTrials.gov/show/NCT03462251

Comments are closed.

Up ↑